Abbott Presents Promising Phase 2b Interferon-free Hepatitis C Results at 2012 Liver Meeting®

[at noodls] – Abbott Park, Illinois (NYSE: ABT) – Results from Abbott’s phase 2b clinical trial, Aviator, demonstrated high sustained viral response rates at 12 weeks post-treatment (SVR12) in all 8- and … more

View todays social media effects on ABT

View the latest stocks trending across Twitter. Click to view dashboard